REGULATORY BRIEFING

China Announcement 48 Export Controls: Beijing Moves to Keep CGT and siRNA Platforms in China

China has proposed adding cell and gene therapy and siRNA platforms to its list of technologies that cannot leave the country. Announcement No. 48, issued by the commerce and science ministries on October 16, 2026, would ban overseas ownership transfers of those platforms while leaving licensing and contract research and manufacturing open. A registration step for covered technology exports already applies, so deals in progress are caught today.

Announcement 48 export controls: latest updates

  • Nov 19, 2026: The US National Security Commission on Emerging Biotechnology warned that licensing deals with Chinese biotechs are shifting capital and know-how to China, after reviewing 57 deals since 2023. Concern that the US could be shut out has grown since China’s proposal.
  • Nov 15, 2026: The public comment period closed. MOFCOM will assess comments before issuing the final catalogue; no date has been set.
  • Oct 22, 2026: A week later, the US Treasury released its COINS Act proposed rule on outbound investment in Chinese biotech, squeezing cross-border deals from both sides.
  • Oct 16, 2026: MOFCOM and MOST issued Announcement No. 48, proposing 40 additions to the export catalogue and requiring pre-export registration for listed technologies from the same day.

Announcement 48 export controls at a glance

RegionChina
InstrumentMOFCOM and MOST Announcement No. 48 of 2026, revising the Catalogue of Technologies Prohibited or Restricted from Export
Legal statusCatalogue changes proposed; interim pre-export registration in force since October 16, 2026
Key datesOct 16, 2026: registration applies. Nov 15, 2026: comments closed. Final catalogue: no date set
Most exposedSponsors acquiring or licensing Chinese CGT and siRNA platforms; investors in China biotech NewCos; viral vector developers
Official sourceMOFCOM spokesperson’s remarks on the catalogue revision
PharmaSource Score144
Impact 6, Reach 4, Likelihood 6
Download the PharmaSource Regulatory Radar

What Announcement 48 is

China’s technology export catalogue lists technologies that are banned from export or need a license. Announcement 48 proposes adding 40 technologies: 23 in artificial intelligence, five in biopharmaceuticals and 12 in photovoltaics. Fourteen would be prohibited and 26 restricted. China already bans export of human cell cloning and gene editing technology, added in its December 2023 revision.

  • Platform bans: Proprietary CGT platforms (262704J) and siRNA drug platforms (262705J) would be prohibited from ownership transfer abroad. Licenses and outsourced research or manufacturing that do not transfer ownership are excluded.
  • Novel target discovery: Technologies to discover and validate wholly new CGT and siRNA targets (262705X, 262706X) would be restricted, so exports need a license, with automatic licensing or facilitation for licensing deals and joint research.
  • Pathogen modification: Specified genetic modification and directed passaging of pathogens (267302J) would be prohibited outright, with no therapeutic exemption.
  • Interim registration: Until the catalogue takes effect, exporters must register on MOFCOM’s technology trade system before transferring ownership abroad, licensing overseas use, or changing the owner or actual controller to a foreign entity. Deals begun but not completed are covered.
  • Outside scope: MOFCOM says outsourced R&D and production services using the technologies are not covered, and products made with controlled technologies fall outside its management.

Where Announcement 48 stands

The catalogue changes are a draft, but the registration step is live. No comparable mechanism accompanied earlier revisions of the catalogue, so companies cannot wait for the final text before acting.

  • Dec 2023: China adds human cell cloning and gene editing to the prohibited list.
  • Oct 16, 2026: Announcement 48 published; interim registration starts.
  • Nov 15, 2026: Comment period closes.
  • Next: MOFCOM assessment and final catalogue, with registration continuing until it takes effect.

What Announcement 48 means for manufacturing and outsourcing

The rule targets who owns a platform, not who uses it. That protects the licensing model behind China’s out-licensing boom while closing the route of buying a Chinese platform company outright.

  • Sponsors licensing Chinese assets: Single-product licenses survive, but sublicensing, manufacturing transfers, use by contract manufacturers and step-in rights need review, and signed but unfinished deals may need registration before technical data moves.
  • Acquirers and NewCo investors: A share deal that gives a foreign acquirer actual control may trigger registration even if IP stays in China. Options that require a later platform assignment could lose value if that assignment is banned.
  • Chinese CDMOs and CROs: Outsourced R&D and manufacturing are outside scope, so service contracts with Chinese providers can continue. Contracts should still state that platform know-how stays with the provider.
  • Viral vector programs: Screen CGT programs against the pathogen entry’s actual criteria; using a viral vector alone does not establish coverage, according to Morgan Lewis.
  • Tech transfer out of China: Licensing a Chinese-developed process for use at a Western CDMO can count as a technology export. Plan for registration and keep transfers tied to a specific product.

For outsourcing leaders, the practical step is to list every China-linked license, NewCo and tech transfer in your portfolio, confirm whether each one moves platform ownership or only product rights, and make sure the Chinese party has registered any covered export before data changes hands.

Why supporters back Announcement 48

“An institutional arrangement for safeguarding national security and building a biosafety barrier.”

MOFCOM spokesperson, Ministry of Commerce
  • Biosafety: Beijing presents the pathogen controls as protection of human health and national biosafety.
  • Keeping core assets: Banning ownership transfers keeps the reusable platforms that make Chinese biotechs valuable inside China, while letting companies earn from licensing.
  • Room for cooperation: MOFCOM says important cooperation is excluded or facilitated, with automatic licensing for joint R&D, public health emergencies and humanitarian aid.
  • Clarity for services: Supporters read the exclusion of outsourced R&D and manufacturing as a sign that China wants its CRO and CDMO sector to keep serving global clients.

Criticisms of Announcement 48

“[China’s Communist Party] seeks dominance in biotechnology as a source of economic power.”

Caitlin Frazer, Executive Director, US National Security Commission on Emerging Biotechnology, Axios

Frazer was describing Beijing’s wider biotech strategy. Her commission, set up by Congress, found that Western licensing deals with Chinese firms now start earlier in drug discovery and send capital and know-how to China. China’s proposal to keep CGT and siRNA platforms at home has added to fears that the US could be shut out of future treatments.

  • Leverage over supply: US critics worry the controls could leave the US shut out of future treatments, while royalties and equity from licensing deals flow back to fund Chinese research.
  • Uncertain edges: How the platform ban applies to share deals without an IP assignment is unresolved, and operators must decide for themselves whether an export needs registration.
  • Retroactive reach: Registration applies to deals signed but not completed, adding a new step to transactions negotiated under the old rules.
  • Two-sided squeeze: A China-side exclusion does not settle the US analysis under the COINS Act or BIOSECURE, so deals face clearance in both capitals.

What’s next for Announcement 48

  • Final catalogue: Watch whether MOFCOM keeps the licensing exclusion for platforms and how it defines a “platform” versus product-specific know-how.
  • Registration practice: Early experience with the MOFCOM system will show how long registration takes and whether it slows signed deals.
  • US response: The COINS Act comment period closes December 7, 2026, and the first BIOSECURE list is due December 18, 2026.
  • Trade talks: Export controls sit alongside the US-China trade truce, which runs to January 10, 2027.
  • Our score: Impact 6, because platform technology transfer out of China would be restricted. Reach 4, because the controls concentrate on CGT and siRNA platforms. Likelihood 6, because comments have closed and the final list is pending, while CDMO services stay outside scope. That gives a PharmaSource Score of 144.

Related articles

Tracking global policies and their impact on biopharma manufacturing
REGULATORY RADAR
Full tracker of regulation changing biopharma manufacturing and supply.
Free to access and updated daily.